Pancreatic cancer is a recalcitrant cancer with one of the lowest 5-year survival rates. A hallmark of pancreatic cancer is the prevalence of oncogenic mutation in the KRAS gene. The KRAS oncogene plays a critical role in the initiation and maintenance of pancreatic tumors and it signaling ...
"KRAS-G12R is unique in that it is a mutation that seems to only occur in pancreatic cancer and not in the other cancer types associated with KRAS mutations, such as lung cancer," said Dr. Chandwani, who is also a member of the Sandra and Edward Meyer Cancer Center and the Englander ...
3. Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring ...
13. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15(6):489-500. 14. Muzumdar MD, Chen P-Y, Dorans...
13. Singh A, Greninger P, Rhodes D, et al. A gene expression signature associated with “K-Ras addiction” reveals regulators of EMT and tumor cell survival. Cancer Cell. 2009;15(6):489-500. 14. Muzumdar MD, Chen P-Y, Dorans KJ, et al. Survival of pancreatic cancer cells lacking ...
The relevance of KRAS mutation alleles to clinical outcome remains inconclusive in pancreatic adenocarcinoma (PDAC). We conducted a retrospective study of 803 patients with PDAC (42% with metastatic disease) at MD Anderson Cancer Center. Overall survival
[7]Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer | NEJM https://www.nejm.org/doi/full/10.1056/NEJMoa2119662
Eser, S., Schnieke, A., Schneider, G., & Saur, D. (2014). Oncogenic KRAS signalling in pancreatic cancer. In British Journal of Cancer (Vol. 111, Issue 5, pp. 817–822). https://doi.org/10.1038/bjc.2014.215 Huang, L., Guo, Z., Wang, F., & Fu, L. (2021). KRAS ...
3. Bekaii-Saab TS, Spira AI, Yaeger R, et al. KRYSTAL-1: updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRASG12C mutation. J Clin Oncol. 2022;40:4s (supp...
13.Golan, Talia , et al. "RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients." Oncotarget 6.27(2015). 14.Soussi T, Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome.Nature Reviews Cancer. 1.3(2001):233-240...